CARTESIAN THERAPEUTICS INC
RNACNASDAQTrading Snapshot
- Day Range
- $7.13 – $7.27
- 52-Week Range
- $5.60 – $11.00
- Volume
- $5.47B
- Avg Volume
- $7.01B
- Shares Outstanding
- 29.4M
- Next Earnings
- Oct 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $733,735
- P/E Ratio
- -1.2
- P/S Ratio
- 147.4x
- EPS (TTM)
- $-5.22
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.3%
Why Investors Own RNAC
- ✓High-growth profile — revenue up -7.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 60% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CARTESIAN THERAPEUTICS INC
RNAC
StockOtter · stockotter.spaceAbout CARTESIAN THERAPEUTICS INC
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
FREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027
New Strong Sell Stocks for July 1st
CZR, RNAC and NSP have been added to the Zacks Rank #5 (Strong Sell) List on July 1, 2026.